Common Stock, par value $0.00033 per share
- Symbol
- PDSB
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
PDS Biotechnology Corporation
PDSBNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On August 11, 2026, PDS Biotechnology Corporation issued a letter to its shareholders which was posted on the Company’s Investor Relations website at pdsbiotech.com/index.php/investors. A copy of the letter to shareholders is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.…
Company context
We are a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer and infectious disease immunotherapies based on our Versamune® T cell activator and Versamune® in combination with our interleukin 12 (IL-12) fused anti-body drug conjugate (ADC), PDS01ADC. In addition, we are developing the Infectimune® T cell-activator in infectious diseases.
Current securities
Registered securities in this filing
PDS BIOTECHNOLOGY CORPORATION · 8-K · Filed 2026-08-11
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.
On August 11, 2026, PDS Biotechnology Corporation issued a letter to its shareholders which was posted on the Company’s Investor
Relations website at pdsbiotech.com/index.php/investors. A copy of the letter to shareholders is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished pursuant to Item
7.01 and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference into
any registration statement or other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ef20079931_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 PDS Biotech Announces Strategic Refocus Prioritizing PDS0301 in Metastatic Colorectal Cancer (mCRC) and Partnership Strategy for PDS0101 PDS0301 Phase 2 clinical data in mCRC and a comprehensive review of capital allocation priorities drive strategic refocus designed to maximize long-term shareholder value PRINCETON, N.J., August 11, 2026 -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on developing targeted immunotherapies for cancer, today issued a Letter to Shareholders from Frank Bedu-Addo, Ph. D., Chief Executive Officer and Director of PDS Biotech: “Dear Fellow Shareholders, Over the past several months, our Board of Directors and management team conducted a comprehensive review of our development portfolio, capital allocation priorities and long-term strategy. Following this review, we believe the best path to creating long-term shareholder value is to prioritize the advancement of PDS0301, our tumor-targeted immunocytokine, while pursuing strategic partnership opportunities for PDS0101. The oncology treatment landscape is rapidly e…
Open exhibit ↗